The cardiologist's role in the management of type 2 diabetes-a review

Carrie Eshelbrenner, Karina Vasquez, Liberty O. Yanze, Rene Oliveros, Robert Chilton

Research output: Contribution to journalReview articlepeer-review


Evidence-based medicine is key to the cardiologist's role in the management of type 2 diabetes. Proven therapies that reduce cardiovascular (CV) events with few off-target effects are imperative. Evidence from epidemiology studies supports the concept that increased blood sugar is correlated with increased CV events. Unfortunately, the lowering of glucose with current agents shows limited benefit in reducing CV events. Metformin in the obese individual reduced CV events and is currently first-line therapy in most clinical practice guidelines. Recently, a meta-analysis reported that current hypoglycemic agents did not improve CV outcomes and were possibly harmful. Possible exceptions come from the Prospective pioglitazone clinical trial in macrovascular events (PROactive), a secondary prevention trial in patients with prior myocardial infarction in which pioglitazone was found to reduce CV events. Glucagon-like peptide-1 (GLP-1) agonists appear to be the most exciting new CV agents, but a dipeptidyl peptidase-4 (DPP4) inhibitor (sitagliptin) combined with a high-dose angiotensin-converting enzyme inhibitor (ACEI) (enalapril) may increase blood pressure and heart rate. Lifestyle modification and proven global risk reduction are still the number one ways to reduce CV events in type 2 diabetes.

Original languageEnglish (US)
Pages (from-to)26-29
Number of pages4
JournalUS Cardiology
Issue number1
StatePublished - Feb 2012


  • Dipeptidyl peptidase-4 inhibitors
  • Exenatide
  • Glucagon-like peptide-1
  • Hypertension
  • Hypoglycemia
  • Pioglitazone
  • Sitagliptin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'The cardiologist's role in the management of type 2 diabetes-a review'. Together they form a unique fingerprint.

Cite this